Evidence map›Paper›PMID 33714704›Full record

ArticleCytotherapy2021

Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predisposition.

Jacques Galipeau, Mauro Krampera, Katarina Leblanc, Jan A Nolta, Donald G Phinney, Yufang Shi, Karin Tarte, Sowmya Viswanathan, Ivan Martin

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cytotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 64 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Mesenchymal Stromal Cells: From Bench to Bedside and Back.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026
    Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Regenerative and translational medicine in COPD: hype and hope.European respiratory review : an official journal of the European Respiratory Society · 2023
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 9 institutions in 7 countries.

Jacques GalipeauDepartment of Medicine, Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin, USA. Electronic address: jgalipeau@wisc.edu.
Mauro KramperaDepartment of Medicine, Section of Hematology, University of Verona, Verona, Italy.
Katarina LeblancDepartment of Laboratory Medicine, Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Jan A NoltaStem Cell Program, University of California Davis, Sacramento, California, USA.
Donald G PhinneyDepartment of Molecular Therapeutics, Scripps Research Institute, Jupiter, Florida, USA.
Yufang ShiInstitute for Translational Medicine, Soochow University, Suzhou, China.
Karin TarteÉtablissement Français du Sang Bretagne, Institute for Health and Medical Research, University of Rennes, Rennes, France.
Sowmya ViswanathanDepartment of Medicine and Institute of Biomedical Engineering, Krembil Research Institute, University Health Network, University of Toronto, Toronto, Canada.
Ivan MartinDepartment of Biomedicine, University Hospital Basel, Basel, Switzerland.
Inserm · FRKarolinska Institutet · SEKrembil Research InstituteScripps Research Institute · USSoochow University · CNUniversity Hospital of Basel · CHUniversity of California, Davis · USUniversity of Verona · ITUniversity of Wisconsin–Madison · US

Funding

A Clinical Indications Prediction (CLIP) Scale for Human Mesenchymal Stem CellsR01HL144089 · NHLBI · UNIVERSITY OF FLORIDA · PI Donald G Phinney · 2018 to 2026
$5.4M
Cytokine primed autologous Mesenchymal Stromal Cells for therapy of colitis.R01DK109508 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI GALIPEAU, JACQUES · 2016 to 2019
$2.1M
NHLBI NIH HHS R01 HL144089NIDDK NIH HHS R01 DK109508
6 · The paper itself

Abstract

The International Society for Cell & Gene Therapy mesenchymal stromal cell (MSC) committee has been an interested observer of community interests in all matters related to MSC identity, mechanism of action, potency assessment and etymology, and it has regularly contributed to this conversation through a series of MSC pre-conferences and committee publications dealing with these matters. Arising from these reflections, the authors propose that an overlooked and potentially disruptive perspective is the impact of in vivo persistence on potency that is not predicted by surrogate cellular potency assays performed in vitro and how this translates to in vivo outcomes. Systemic delivery or extravascular implantation at sites removed from the affected organ system seems to be adequate in affecting clinical outcomes in many pre-clinical murine models of acute tissue injury and inflammatory pathology, including the recent European Medicines Agency-approved use of MSCs in Crohn-related fistular disease. The authors further propose that MSC viability and metabolic fitness likely dominate as a potency quality attribute, especially in recipients poised for salutary benefits as defined by emerging predictive biomarkers of response.

Indexed as

Mesenchymal Stem CellsMesenchymal Stem Cell TransplantationAnimalsCell- and Tissue-Based TherapyGenetic TherapyMicebiomarkersclinical useefferocytosisISCT MSC committeemesenchymal stromal cellspotencyviability

Identifiers

PMID33714704
PMCPMC11708105
OpenAlexW3135534096

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.